ABC 60mg / 3TC 30mg / DTG 5mg, disp. tab.
Valid Article
ABACAVIR (ABC)/ LAMIVUDINE (3TC)/ DOLUTEGRAVIR (DTG) paed
Full Name
Paediatric abacavir/ lamivudine/ dolutegravir (pALD) fixed-dose combination
Therapeutic Action
Paediatric fixed-dose combination of three antiretrovirals (pALD):
- nucleotide reverse transcriptase inhibitors (NRTI) : abacavir (ABC) and lamivudine (3TC)
- Integrase strand transfer inhibitor (INSTI): dolutegravir (DTG)
Indications
HIV infection, according to dosage recommended by WHO.
First-line ART regimen for children at least 3 months of age and weighing 6 to 24.9 kg.
Instructions for use
Paediatric use only.
Tablets should be dispersed in water only and given orally once per day.
This pALD fixed-dose combination (Abacavir/Lamivudine/Dolutegravir 60/30/5 mg) replaces the administration of separate components of Abacavir/Lamivudine 120/60mg + Dolutegravir 10mg in children from 6 to < 25 kg.
Separate components Abacavir/Lamivudine 120/60mg + Dolutegravir10mg will still be used for children from 3 to 5.9 kg.
Storage
- Below 25ºC - Protect from humidity
- Keep the bottle tightly closed. Do not remove the desiccant.